Alzheimer’s

#Alzheimer's #Neurodegenerative disorders #Neuroscience

Novel peptide targets early molecular trigger of Alzheimer’s

A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases.  The Proceedings of the National Academy of Sciences (PNAS) will publish results of the groundbreaking study demonstrating a customised,… Read More

#Editor's Choice #News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Animal models #Neurodegenerative disorders #University of Glasgow

Hope for drug that slows neurodegenerative disease

Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD).  The study was led by researchers at the University of Glasgow’s new Advanced… Read More

#Editor's Choice #News

Brain inflammation
#Alzheimer's #Brain disease #Neurodegenerative disorders #Neuroinflammation #Neurology #Parkinson's

Covid-19 triggers inflammation in the brain

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ… Read More

#Covid-19 #News

Tau proteins
#Alzheimer's #Cognitive impairment #Dementia #Tau protein

Study reveals new therapeutic target in neurodegenerative disease

Early-cognitive decline may result from a shift in the ratio of a protein sub-type in our brain cells triggering cell-loss, according to a new study. The discovery, published in Scientific Reports, provides a new therapeutic target to prevent the onset of neurodegenerative diseases including dementia and Alzheimer’s. It is the… Read More

#News

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News

Jigsaw puzzle of the brain
#Alzheimer's #Antibody #Clinical trial #Cognitive impairment #Drug development #Drug discovery #Phase III trial

New Alzheimer’s treatment reduces decline in Phase III trial

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain.  Eisai and Biogen’s anti-amyloid beta (Aβ) protofibril antibody lecanemab met the primary endpoint and… Read More

#News

#Alzheimer's #Drug discovery #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Tau protein

Taking a new approach to tackle neurodegenerative diseases

Listen to this article on the DDW Podcast: William Erhardt, President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases.  New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by… Read More

#Editor's Choice #Exclusive Content

#Alzheimer's #Cancer research #Colorectal cancer #Drug discovery #Eczema #FDA #Plaque Psoriasis

This week in drug discovery (12-16 September)

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. … Read More

#News

CT scans of the brain
#Alzheimer's #Cognitive impairment #Drug discovery #US patent

Potential Alzheimer’s drug receives US patent

The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment. ACD856 is part of AlzeCure Pharma’s NeuroRestore platform, which it is hoped could provide treatments for Alzheimer’s, Parkinson’s disease and depression. Read More

#News

#Alzheimer's #Business #Immunology / Virology & Vaccines #Oncology

This week in drug discovery (8-12 August)  

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer… Read More

#News

#Alzheimer's #Collaboration #Neurology #US

Cerevance teams up with Merck (MSD) on Alzheimer’s project  

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   Cerevance will receive an upfront payment of $25 million from Merck (MSD) and could receive development and commercial milestone payments of up to… Read More

#News

#Alzheimer's #Biogen #EIT Health #Neurology

Start-ups win EU-pharma Alzheimer’s contest  

Two start-ups have won a competition organised by EIT Health and pharmaceutical company Biogen which aimed at identifying solutions for Alzheimer’s disease.   French start-up Five Lives and Dutch start-up Neurocase were respectively placed first and second in the ‘neurotechprize’ competition. The winners were announced during a ceremony… Read More

#News

#Alzheimer's #Biotechnology #Mouse models #Neurodegenerative disorders

Novel drug effective in a mouse model of Alzheimer’s disease

Neuro-Bio, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, has found its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease. Publishing their work in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI)… Read More

#News

#Alzheimer's #Genetics / genomes

Scientists uncover new genetic factors for Alzheimer’s disease  

Scientists have discovered 75 genetic risk factors for Alzheimer’s disease in research which could help with the development of new therapies.   An international group of scientists from Inserm, Institut Pasteur de Lille, Lille University Hospital, and Université de Lille and the University of Bristol… Read More

#News

#Alzheimer's #Clinical trials #Pharma

Winterlight Labs launches speech assessment collaboration  

Digital biomarkers developer Winterlight Labs and memory clinic Alzheimer Center Amsterdam will work together on a project to decentralise assessments of patients’ cognition and function in the study of preclinical Alzheimer’s disease.   The project will see Alzheimer Center Amsterdam develop a remote measurement toolbox, integrating Winterlight’s digital… Read More

#News

#Alzheimer's #Events #Neuroscience

AlzeCure gets late-breaking neuroscience abstract accepted  

AlzeCure Pharma, a pharmaceutical company that develops small molecule candidate drugs for diseases affecting the central nervous system, has announced that an abstract on clinical data of its candidate drug ACD856 has been accepted for a poster presentation at AD/PD 2022, which this year will be held in Barcelona on… Read More

#News